<DOC>
	<DOCNO>NCT02456675</DOCNO>
	<brief_summary>A Phase 2 , open-label study evaluate safety efficacy INCB040093 monotherapy combination therapy itacitinib ( INCB039110 ) subject relapse refractory Hodgkin Lymphoma .</brief_summary>
	<brief_title>INCB040093 INCB040093 Combined With Itacitinib ( INCB039110 ) Relapsed/Refractory Hodgkin Lymphoma</brief_title>
	<detailed_description />
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Hodgkin Disease</mesh_term>
	<criteria>Men woman , age 18 year old Histologically confirm diagnosis classical HL Must relapse refractory autologous stem cell transplant ( ASCT ) and/or 2 prior chemotherapy regimen Must prior treatment brentuximab vedotin candidate treatment brentuximab vedotin Eastern Cooperative Oncology Group ( ECOG ) 0 2 Laboratory parameter within protocoldefined range Received investigational study drug within 28 day 5 halflives ( whichever longer ) prior receive first dose study drug . Received approved anticancer medication within 21 day 5 halflives ( whichever longer ) prior receive first dose study drug EXCEPT steroid ≤ 10 mg prednisone daily ( equivalent ) . Has unresolved toxicity ≥ Grade 2 previous anticancer therapy Received autologous stem cell transplant within 28 day allogeneic transplant within 3 month prior first dose study drug History lymphoma involve central nervous system Evidence active prior hepatitis infection .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Refractory Hodgkin lymphoma</keyword>
	<keyword>Relapsed Hodgkin Lymphoma</keyword>
</DOC>